Perrone F - Search Results

1

Pharmacokinetic evaluation of capecitabine in breast cancer.

Daniele G, Gallo M, Piccirillo MC, Giordano P, D'Alessio A, Del Giudice A, La Porta ML, Perrone F, Normanno N, De Luca A. Daniele G, et al. Among authors: perrone f. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):225-35. doi: 10.1517/17425255.2013.759939. Epub 2013 Jan 10. Expert Opin Drug Metab Toxicol. 2013. PMID: 23301520 Review.

2

Survey of modalities of toxicity assessment and reporting in noncomparative prospective studies of chemotherapy in breast cancer.

Perrone F, De Maio E, Maione P, Di Maio M, Ottaiano A, Pensabene M, Di Lorenzo G, Vernaglia Lombardi A, Gallo C. Perrone F, et al. J Clin Oncol. 2002 Jan 1;20(1):52-7. doi: 10.1200/JCO.2002.20.1.52. J Clin Oncol. 2002. PMID: 11773153 Review.

3

Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas.

D'Antonio A, Losito S, Pignata S, Grassi M, Perrone F, De Luca A, Tambaro R, Bianco C, Gullick WJ, Johnson GR, Iaffaioli VR, Salomon DS, Normanno N. D'Antonio A, et al. Among authors: perrone f. Int J Oncol. 2002 Nov;21(5):941-8. Int J Oncol. 2002. PMID: 12370739

4

Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?

Normanno N, Di Maio M, Perrone F, Campiglio M. Normanno N, et al. Among authors: perrone f. J Clin Oncol. 2004 May 15;22(10):2035-6; author reply 2036-7. doi: 10.1200/JCO.2004.99.337. J Clin Oncol. 2004. PMID: 15143103 No abstract available.

5

Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro?

De Luca A, Grassii M, Maiello MR, Di Maio M, Mancino M, De Maio E, Gridelli C, Perrone F, Normanno N. De Luca A, et al. Among authors: perrone f. Anticancer Res. 2004 Sep-Oct;24(5A):2985-9. Anticancer Res. 2004. PMID: 15517905 Free article.

6

Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials.

Perrone F, Di Maio M, Budillon A, Normanno N. Perrone F, et al. Curr Opin Oncol. 2005 Mar;17(2):123-9. doi: 10.1097/01.cco.0000155048.51919.eb. Curr Opin Oncol. 2005. PMID: 15725916 Review.

7

Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F. Di Maio M, et al. Among authors: perrone f. J Cell Physiol. 2005 Dec;205(3):355-63. doi: 10.1002/jcp.20402. J Cell Physiol. 2005. PMID: 15895392 Review.

8

Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.

Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F; NCI-Naples Breast Cancer Group. Normanno N, et al. Among authors: perrone f. Endocr Relat Cancer. 2005 Dec;12(4):721-47. doi: 10.1677/erc.1.00857. Endocr Relat Cancer. 2005. PMID: 16322319 Review.

9

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Morabito A, et al. Among authors: perrone f. Oncologist. 2006 Jul-Aug;11(7):753-64. doi: 10.1634/theoncologist.11-7-753. Oncologist. 2006. PMID: 16880234 Free article. Review.

10

Identification of cripto-1 as a novel serologic marker for breast and colon cancer.

Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, De Luca A, Jones B, Balogh G, Russo J, Mailo D, Palaia R, D'Aiuto G, Botti G, Perrone F, Salomon DS, Normanno N. Bianco C, et al. Among authors: perrone f. Clin Cancer Res. 2006 Sep 1;12(17):5158-64. doi: 10.1158/1078-0432.CCR-06-0274. Clin Cancer Res. 2006. PMID: 16951234

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

681 results

Search Page